<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="96">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555827</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX2011/19</org_study_id>
    <nct_id>NCT01555827</nct_id>
  </id_info>
  <brief_title>Retinal Neurodegenerative Signs in Alzheimer's Diseases</brief_title>
  <acronym>SIGNAL</acronym>
  <official_title>Retinal Neurodegenerative Signs in Alzheimer's Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A few studies suggest that patients suffering from neurodegenerative diseases (such a&#xD;
      multiple sclerosis or Alzheimer's disease (AD)) show decreased thickness of the retinal nerve&#xD;
      fiber layer (RNFL), indicating axonal degeneration. High-definition spectral domain optical&#xD;
      coherence tomography (SD-OCT), performed without radiation in a few seconds per eye, offers a&#xD;
      precise and standardized estimation of this parameter, which could constitute a biomarker for&#xD;
      cerebral axonal degeneration. These RNFL deficits might even be the earliest sign of AD,&#xD;
      prior to damage of the hippocampal region that impacts memory.&#xD;
&#xD;
      Besides, some associations of AD with some degenerative diseases of the eye (glaucoma,&#xD;
      microvascular abnormalities, age-related macular degeneration (AMD)) have also been reported.&#xD;
&#xD;
      It therefore seems interesting to determine whether RNFL thickness, and other ocular&#xD;
      parameters, may give some indications for a better detection of AD and cognitive decline in&#xD;
      the elderly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2012</start_date>
  <completion_date type="Actual">June 7, 2014</completion_date>
  <primary_completion_date type="Actual">June 7, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RNFL thickness measured on a peri-papillary scan of SD-OCT examination.</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glaucomatous optic nerve damage observed on colour photographs (cup/disc ratio)</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal microvascular abnormalities (microaneurysms, micro-hemorrhage, cotton wool spots, arteriovenous nicking), observed on retinal colour photography</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular abnormalities observed on retinal colour photographs (drusen, pigmentary abnormalities, neovascular AMD, atrophic AMD, other retinal diseases)</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular abnormalities observed on macular scans in SD-OCT (drusen, pigmentary abnormalities, neovascular AMD, atrophic AMD, epiretinal membranes, other retinal diseases).</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular abnormalities observed in autofluorescence imaging (increased autofluorescence, decreased autofluorescence, reticular drusen, atrophic AMD, other abnormalities)</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular and peripheral abnormalities diagnosed in wide-field retinal imaging</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal blood flow velocity (RFI)</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>inclusion visit (day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>axial length</measure>
    <time_frame>inclusion visit (day 0)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ophthalmological examination &amp; Questionnaire</intervention_name>
    <description>The following examinations will be performed, after pupil dilation:&#xD;
Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)&#xD;
Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)&#xD;
Wide-field colour and autofluorescence imaging (Optomap)&#xD;
Measure of intra-ocular pressure (pneumotonometer)&#xD;
The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:&#xD;
Age, gender&#xD;
educational level&#xD;
smoking&#xD;
cardiovascular diseases, current medications&#xD;
scores at neuropsychological tests</description>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria for AD cases:&#xD;
&#xD;
          -  Diagnosis of probable AD, defined according to the NINCDS-ARDRA criteria51&#xD;
&#xD;
          -  Light to moderate severity of the disease, defined by a MMSE score &gt;10 (global&#xD;
             evaluation of cognition)&#xD;
&#xD;
          -  Patient aged 50 years or more&#xD;
&#xD;
          -  Patient benefiting from social insurance&#xD;
&#xD;
        Inclusion criteria for controls:&#xD;
&#xD;
          -  Absence of suspicion of dementia, based on normal performance according to age and&#xD;
             educational level at neuropsychological testing defined as:&#xD;
&#xD;
          -  Free recall ≥17 and total recall ≥40 for the Free and Cued Selective Reminding Test&#xD;
             (Grober and Buschke test 52) MMSE ≥ norm for age and educational level (defined by&#xD;
             mean - 1 SD)&#xD;
&#xD;
          -  Isaac's set test ≥ norm for age and educational level (defined by mean - 1 SD)&#xD;
&#xD;
          -  Matched to age and gender of the cases&#xD;
&#xD;
          -  Patient benefiting from social insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria for all patients :&#xD;
&#xD;
          -  History of Parkinson's disease or other neurodegenerative disorder&#xD;
&#xD;
          -  History of Horton's disease&#xD;
&#xD;
          -  History of inflammatory neuropathies (in particular Devic's disease, multiple&#xD;
             sclerosis)&#xD;
&#xD;
          -  History of vascular ischemic neuropathies and chronic intracranial hypertension&#xD;
&#xD;
          -  History of pituitary tumors&#xD;
&#xD;
          -  Presence of diseases (systemic and/or ocular diseases) or behavioural or cognitive&#xD;
             symptoms incompatible with eye examination&#xD;
&#xD;
          -  Known diabetes&#xD;
&#xD;
          -  Person under tutorship or curatorship, person unable to express consent&#xD;
&#xD;
        Additional exclusion criteria for AD cases:&#xD;
&#xD;
          -  Dementia of other cause than AD&#xD;
&#xD;
          -  Severe AD, defined by MMSE score ≤ 10&#xD;
&#xD;
        Additional exclusion criteria for controls:&#xD;
&#xD;
          -  Presence of dementia, of whatever cause&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François KOROBELNIK, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Delcourt Cécile, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>ISPED, bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bordeaux - hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retina</keyword>
  <keyword>ALzheimer's disease</keyword>
  <keyword>neurodegenerative signs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

